Zacks Research Analysts Lower Earnings Estimates for A

Agilent Technologies, Inc. (NYSE:A) – Stock analysts at Zacks Research reduced their Q2 2025 EPS estimates for shares of Agilent Technologies in a research report issued on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $1.26 per share for the quarter, down from their previous estimate of $1.33. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.57 per share. Zacks Research also issued estimates for Agilent Technologies’ Q4 2025 earnings at $1.58 EPS, Q3 2026 earnings at $1.53 EPS, Q4 2026 earnings at $1.65 EPS, FY2026 earnings at $6.03 EPS, Q1 2027 earnings at $1.61 EPS and FY2027 earnings at $6.61 EPS.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. The business had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion.

Other research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. decreased their price objective on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 26th. Wells Fargo & Company reduced their target price on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a report on Monday, December 9th. Robert W. Baird decreased their price target on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Citigroup lifted their target price on shares of Agilent Technologies to $165.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. Finally, Barclays upgraded Agilent Technologies from an “underweight” rating to an “equal weight” rating and increased their price target for the stock from $135.00 to $145.00 in a report on Monday, February 10th. Seven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Agilent Technologies currently has a consensus rating of “Moderate Buy” and an average price target of $146.15.

Agilent Technologies Trading Down 1.6 %

A stock opened at $120.23 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20. Agilent Technologies has a 52 week low of $117.17 and a 52 week high of $155.35. The company’s 50-day simple moving average is $137.07 and its 200 day simple moving average is $137.45. The company has a market capitalization of $34.28 billion, a PE ratio of 27.64, a price-to-earnings-growth ratio of 3.43 and a beta of 1.11.

Hedge Funds Weigh In On Agilent Technologies

Hedge funds have recently modified their holdings of the business. Vestal Point Capital LP purchased a new stake in Agilent Technologies in the third quarter valued at approximately $14,848,000. Sienna Gestion raised its holdings in shares of Agilent Technologies by 29.8% in the fourth quarter. Sienna Gestion now owns 78,445 shares of the medical research company’s stock worth $10,537,000 after acquiring an additional 17,991 shares during the last quarter. S.E.E.D. Planning Group LLC grew its stake in Agilent Technologies by 12.7% in the 4th quarter. S.E.E.D. Planning Group LLC now owns 42,587 shares of the medical research company’s stock worth $5,721,000 after acquiring an additional 4,805 shares during the period. Sequoia Financial Advisors LLC boosted its position in shares of Agilent Technologies by 8.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 33,898 shares of the medical research company’s stock worth $4,554,000 after acquiring an additional 2,664 shares during the last quarter. Finally, Miracle Mile Advisors LLC purchased a new stake in Agilent Technologies during the fourth quarter valued at about $362,000.

Insider Buying and Selling at Agilent Technologies

In other news, VP Rodney Gonsalves sold 1,908 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $121.98, for a total value of $232,737.84. Following the sale, the vice president now owns 21,786 shares in the company, valued at $2,657,456.28. This represents a 8.05 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the sale, the chief executive officer now directly owns 39,652 shares in the company, valued at $5,947,800. This trade represents a 4.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be paid a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a yield of 0.83%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies’s dividend payout ratio (DPR) is 22.76%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.